Inhibikase Therapeutics, Inc. stock is up 12.64% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 November’s closed higher than October.
Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD.